

## Research Article

# Biochemical and Molecular Analysis of *Staphylococcus aureus* Clinical Isolates from Hospitalized Patients

**Amit Karmakar, Parimal Dua, and Chandradipa Ghosh**

Microbiology Laboratory, Department of Human Physiology with Community Health, Vidyasagar University, Paschim Medinipur, West Bengal 721102, India

Correspondence should be addressed to Chandradipa Ghosh; [chandradipa.ghosh@gmail.com](mailto:chandradipa.ghosh@gmail.com)

Received 26 February 2016; Revised 29 March 2016; Accepted 10 April 2016

Academic Editor: Luis Caetano M. Antunes

Copyright © 2016 Amit Karmakar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Staphylococcus aureus* is opportunistic human as well as animal pathogen that causes a variety of diseases. A total of 100 *Staphylococcus aureus* isolates were obtained from clinical samples derived from hospitalized patients. The presumptive *Staphylococcus aureus* clinical isolates were identified phenotypically by different biochemical tests. Molecular identification was done by PCR using species specific 16S rRNA primer pairs and finally 100 isolates were found to be positive as *Staphylococcus aureus*. Screened isolates were further analyzed by several microbiological diagnostics tests including gelatin hydrolysis, protease, and lipase tests. It was found that 78%, 81%, and 51% isolates were positive for gelatin hydrolysis, protease, and lipase activities, respectively. Antibiogram analysis of isolated *Staphylococcus aureus* strains with respect to different antimicrobial agents revealed resistance pattern ranging from 57 to 96%. Our study also shows 70% strains to be MRSA, 54.3% as VRSA, and 54.3% as both MRSA and VRSA. All the identified isolates were subjected to detection of *mecA*, *nuc*, and *hly* genes and 70%, 84%, and 40% were found to harbour *mecA*, *nuc*, and *hly* genes, respectively. The current investigation is highly important and informative for the high level multidrug resistant *Staphylococcus aureus* infections inclusive also of methicillin and vancomycin.

## 1. Introduction

*Staphylococcus aureus* is one of the most harmful species of staphylococci encountered. It is the leading cause of bacteremia, pneumonia, myocarditis, acute endocarditis, pericarditis, osteomyelitis, encephalitis, meningitis, chorioamnionitis, mastitis, and scalded skin syndrome [1]. Human morbidity and mortality in hospital settings are largely caused by staphylococcal bacteremia [2]. The pathogenic capacity of *Staphylococcus aureus* is clearly dependent on its production of exoproteins and toxins. The species is identified on the basis of a variety of conventional physiological or biochemical characters. The key characters for *Staphylococcus aureus* are colony pigment, free coagulase, clumping factor, protein A, heat-stable nuclease, lipase, and acid production from mannitol [1]. In addition, *Staphylococcus aureus* can be identified by PCR methods. 16S rRNA gene is reported to be the most useful and extensively investigated taxonomic marker molecules [3].

Due to excessive and uncontrolled use of antibiotics the organism becomes multidrug resistant leaving few therapeutic options for the treatment against it [4]. The emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) in hospital-acquired (HA) infections highlights this species as a potential pathogen that is able to cope with the antimicrobial agent [5]. The *mecA* gene [6, 7] synthesizes penicillin binding protein (PBP2a) and it is the cause of methicillin resistance in MRSA. This gene resides on the staphylococcal cassette chromosome (SCC) [8]. Staphylococcal cassette chromosome is a large genetic mobile element which varies in size and genetic composition among the strains of MRSA [9]. Colonized hospital personnel and infected patients are the main source of MRSA [10]. Knowledge of selection of the antibiotics for treatment is important as antibiotic responsiveness pattern of MRSA may vary from region to region [11]. To treat staphylococcal infections, various classes of antibiotics including beta-lactams, glycopeptides, lipopeptide, oxazolidinones, aminoglycosides, macrolides, and fluoroquinolones

TABLE 1: Primer sequences of 16S rRNA, *mecA*, *nuc*, and *hly* genes of *Staphylococcus aureus*.

Primer	Direction	Sequences (5'-3')	Amplicon sizes (bp)	Reference
16S rRNA	F	GTA GGT GGC AAG CGT TAT CC	228	[19]
	R	CGCACATCAGCGTCAG		
<i>mecA</i>	F	GTG AAG ATA TAC CAA GTG ATT	147	[20]
	R	ATG CGC TAT AGA TTG AAA GGA T		
<i>nuc</i>	F	GCGATTGATGGTGATACGGTT	270	[21]
	R	AGCCAAGCCTTGACGAACTAAAAGC		
<i>hly</i>	F	GTGCACTTACTGACAATAGTGC	309	[22]
	R	GTTGATGAGTAGCTACCTTCAGT		

were used [12–15]. Resistance of staphylococci occurs with a variety of antimicrobial agents as well as vancomycin. Therefore, vancomycin resistance is another problem for the treatment of infections caused by this bacterium [16].

The present work was planned to identify and characterize *Staphylococcus aureus* isolates collected from postoperative wound swab of male and female patients hospitalized in the various departments of Midnapore Medical College and Hospital, Midnapore, West Bengal, India. The objectives of the present study were to find out the rate of MRSA and vancomycin resistant *Staphylococcus aureus* (VRSA) in hospital-acquired infections and to determine the antibiotic responsiveness pattern.

## 2. Materials and Methods

**2.1. Bacterial Isolates and Culture Methods.** From January 2013 to October 2014, a total of 165 nonduplicate bacterial isolates were collected from the Male Surgical Wards, Orthopedic Ward, and Burn and Wound Section of Midnapore Medical College and Hospital, Midnapore, West Bengal, India. Only strains obtained from a pure culture were included. Only the first strain from each patient was included. All the strains were collected aseptically, transferred into mannitol salt agar (MSA) media, HiMedia (Mumbai), and incubated overnight at 37°C [17].

**2.2. Isolation and Phenotypic Identification of *Staphylococcus aureus*.** Each isolated bacterial sample from MSA media was initially evaluated on 5% sheep blood agar and incubated overnight at 37°C. Each culture underwent Gram staining and was tested for production of catalase, free coagulase, yellow pigment, and thermonuclease (TNase), according to Lancette and Tatini [18].

**2.3. Molecular Identification through PCR Amplification of 16S rRNA Gene.** The bacterial isolates which were found to be *Staphylococcus aureus* by specific phenotypic features were further tested by PCR for confirmation using specific primer pairs of 16S rRNA (Table 1). These primers amplify 228 bp region of 16S rRNA gene fragment of *Staphylococcus aureus*, which is highly conserved at species level. PCR programming was begun with an initial denaturation step at 94°C for 2 min followed by 35 cycles of 94°C for 30 sec, 50°C for 30 sec, and

72°C for 45 sec, ending with a final extension step at 72°C for 4 min. *S. aureus* ATCC 25923 was used as positive control in this experiment.

**2.4. Biochemical Characterization of *Staphylococcus aureus* Strains.** The bacterial strains that were confirmed as *Staphylococcus aureus* by species specific 16S rRNA screening were further analyzed by several microbiological diagnostics tests including mannitol fermentation and growth on high salt concentration, gelatin hydrolysis, urea hydrolysis, protease activity on milk agar medium, lipase production on egg yolk agar medium (HiMedia, Mumbai), and hydrolysis of esculin by standard methods [23–26]. Hemolytic activity was determined on sheep blood agar (15 mL of 5% sheep blood in Trypticase soy agar overlaid on 10 mL of blood agar base) according to Rodgers et al. [27].

**2.5. Antibiotic Susceptibility Pattern of Isolated *Staphylococcus aureus* to Some Antimicrobial Agents and Detection of VRSA.** The susceptibility of the *Staphylococcus aureus* isolates to different antimicrobial agents was done by disk diffusion method using commercial disks obtained from HiMedia, Mumbai [28]. The antimicrobial disks were as follows: ampicillin (30 µg), streptomycin (10 µg), kanamycin (30 µg), erythromycin (10 µg), chloramphenicol (30 µg), ceftioxin (30 µg), nalidixic acid (30 µg), and novobiocin (30 µg). Clinical strains were categorized as susceptible and resistant according to evaluation criteria developed by the Clinical and Laboratory Standards Institute (CLSI) guidelines [29]. To identify VSSA and VRSA, MIC of vancomycin was determined by the microbroth dilution method using the Mueller-Hinton broth according to the Clinical Laboratory Standards Institute guidelines [29]. *Staphylococcus aureus* ATCC 29213 strains were used as vancomycin-susceptible controls and *Enterococcus faecalis* ATCC 51299 as vancomycin resistant control.

**2.6. Detection of *mecA*, *nuc*, and *hly* Genes.** *Staphylococcus aureus* isolates were subjected to the detection of *mecA*, *nuc*, and *hly* genes by PCR using specific primer pairs (Table 1). The amplification was performed in a Thermal Cycler (Eppendorf, Germany) beginning with an initial denaturation step at 95°C for 2 min followed by 35 cycles of 94°C for 1 min, 55°C for 45 sec, 50° for 50 sec, and 52° for 40 sec for *mecA*, *nuc*, and

TABLE 2: Phenotypic characteristics for identification of *Staphylococcus aureus*.

Source of the isolates	Number of examined samples	Number of <i>S. aureus</i> isolates	Colony pigment			Gram stain Number* (%)	Catalase activity Number* (%)	Coagulase activity Number* (%)	Inase activity Number* (%)
			White Number* (%)	Creamy Number* (%)	Yellow Number* (%)				
Male Surgical Ward	80	45	5 (11)	15 (33)	25 (55)	45 (100)	42 (93)	37 (83)	
Orthopedic Ward	70	50	18 (36)	12 (24)	20 (40)	50 (100)	45 (90)	42 (83)	
Burn and Wound Section	15	5	0 (0)	2 (40)	3 (60)	5 (100)	5 (100)	5 (100)	
Total	165	100	23 (23)	29 (29)	48 (48)	100 (100)	92 (92)	84 (84)	

\* Positive number; percentage is presented in parenthesis.

TABLE 3: Important biochemical markers of *Staphylococcus aureus* isolates.

Source of the isolates	Mannitol fermentation with high salt concentration Number* (%)	Gelatinase activity Number* (%)	Urease activity Number* (%)	Protease activity Number* (%)	Lipase production Number* (%)	Esculin hydrolysis Number* (%)
Male Surgical Ward	45 (100)	33 (73)	34 (76)	36 (80)	22 (49)	5 (11)
Orthopedic Ward	50 (100)	40 (80)	35 (70)	41 (82)	25 (50)	5 (10)
Burn and Wound Section	5 (100)	5 (100)	4 (80)	4 (80)	4 (80)	0 (0)
Total	100 (100)	78 (78)	73 (73)	81 (81)	51 (51)	10 (10)

\* Positive number; percentage is presented in parenthesis.

TABLE 4: Hemolytic activity of clinical isolates of *Staphylococcus aureus*.

Source of the isolates	Number of examined samples	Alpha Number* (%)	Beta Number* (%)	Gamma Number* (%)
Male Surgical Ward	45	25 (56)	15 (33)	5 (11)
Orthopedic Ward	50	18 (36)	20 (40)	12 (24)
Burn and Wound Section	5	0 (0)	5 (100)	0 (0)
Total	100	43 (43)	40 (40)	17 (17)

\* Positive number; percentage is presented in parenthesis.

TABLE 5: Susceptibility and resistance pattern of *Staphylococcus aureus* to 8 antimicrobial agents.

Antibiotics	% resistant	% sensitive
Ampicillin (30 mcg)	96	4
Chloramphenicol (30 mcg)	57	53
Streptomycin (10 mcg)	75	25
Erythromycin (10 mcg)	81	19
Kanamycin (30 mcg)	74	26
Nalidixic acid (30 mcg)	89	11
Novobiocin (30 mcg)	75	25
Cefoxitin (30 mcg)	70	30

*hly* gene, respectively, and a common extension for 72°C for 2 min, ending with a final extension step at 72°C for 4 min. For rapid DNA extraction from *Staphylococcus aureus* one to five bacterial colonies were suspended in 50 µL of sterile Milli Q water (Millipore-Synergy®, India) and heated at 99°C for 10 min in a 500 µL Eppendorf tube. After centrifuge at 14000 r.p.m. for 10 min in a mini centrifuge (Eppendorf, Germany), 2 µL of the supernatant was used as template.

### 3. Results

In the present study 165 nonduplicate samples were collected from hospitalized patients. Among 165 samples, 100 strains (60.60%) were isolated from a selective MSA media and then these isolates were identified for *Staphylococcus aureus* by different biochemical tests (Table 2). Gram staining, catalase, coagulase, and thermonuclease were important phenotypic

identifying markers of *Staphylococcus aureus*. In this study we found that 100%, 92%, and 84% isolates were positive for catalase, coagulase, and heat-stable nuclease, respectively (Table 2). All *Staphylococcus aureus* isolates (100) in this study were confirmed by PCR using the species specific primer pair (Table 1). The enzyme gelatinase was secreted by *Staphylococcus aureus* liquefy gelatin protein. Present study also showed that 78% of *Staphylococcus aureus* isolates were able to produce gelatinase. In Table 3, 81%, 51%, and 48% of isolated strains produced protease, lipase, and nonwhite pigmented colonies, respectively. Present study showed that 40% of *Staphylococcus aureus* isolates were able to produce clearing zone surrounding their growth on blood agar media (Table 4) demonstrating that they can produce hemolysin. Rates of resistance pattern of *Staphylococcus aureus* ranged from 57 to 96%. Resistance of *Staphylococcus aureus* isolates to ampicillin (96%), cefoxitin (70%), kanamycin (74%), erythromycin (81%), streptomycin (75%), nalidixic acid (89%), novobiocin (75%), and chloramphenicol (57%) was found (Table 5). All *Staphylococcus aureus* strains isolated in this study were found to be multidrug resistant. In the present study we have found that the prevalence rate of MRSA is 70%. Our study also found that 54.3% of the isolated *Staphylococcus aureus* were vancomycin resistant (Table 6) and 54.3% of the methicillin-resistant *Staphylococcus aureus* were resistant to vancomycin. According to the CLSI guideline [29] strains having a vancomycin MIC of 4–8 µg/mL were vancomycin-intermediate *Staphylococcus aureus*. Further we had found that 38.6% strains were vancomycin-intermediate *Staphylococcus aureus*. All phenotypically identified methicillin resistant *Staphylococcus aureus* (MRSA) strains possessed *mecA* gene. An extracellular thermostable endonuclease

TABLE 6: Minimum inhibitory concentration of vancomycin of *Staphylococcus aureus* clinical isolates.

Vancomycin MIC ( $\mu\text{g/mL}$ )	MRSA (N = 70)			MSSA (N = 30)		
	VSSA Number* (%)	VISA Number* (%)	VRSA Number* (%)	VSSA Number* (%)	VISA Number* (%)	VRSA Number* (%)
0.25	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
0.5	3 (4.28)	0 (0)	0 (0)	18 (60)	0 (0)	0 (0)
1	2 (2.85)	0 (0)	0 (0)	12 (40)	0 (0)	0 (0)
2	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
4	0 (0)	10 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)
8	0 (0)	17 (24.3)	0 (0)	0 (0)	0 (0)	0 (0)
16	0 (0)	0 (0)	36 (51.4)	0 (0)	0 (0)	0 (0)
32	0 (0)	0 (0)	2 (2.9)	0 (0)	0 (0)	0 (0)
Total	5 (7.1)	27 (38.6)	38 (54.3)	30 (100)	0 (0)	0 (0)

\* Positive number; percentage is presented in parenthesis; VSSA: vancomycin-susceptible *Staphylococcus aureus*; VISA: vancomycin-intermediate *Staphylococcus aureus*; VRSA: vancomycin resistant *Staphylococcus aureus*; MRSA: methicillin-resistant *Staphylococcus aureus*; MSSA: methicillin-susceptible *Staphylococcus aureus*.

(TNase) which cuts both DNA and RNA was produced by *Staphylococcus aureus* characterized by its gene *nuc* specific for *Staphylococcus aureus* [21]. Eighty-four % strains were found to harbour *nuc* gene. PCR analysis also revealed 40 strains to carry *hly* gene responsible for beta hemolysis.

#### 4. Discussion

In the present study a total of one hundred (60.60%) isolates of clinical bacterial samples from Male Surgical Wards, Orthopedic Ward, and Burn and Wound Section of Midnapore Medical College and Hospital, Midnapore, West Bengal, India, were confirmed to be *Staphylococcus aureus*. Vijayalakshmi [30] reported that a surgical site infection by *Staphylococcus aureus* has found 43.2% in Hyderabad, India. Gram staining, catalase, coagulase, and thermonuclease were important phenotypic identifying markers of *Staphylococcus aureus* [1]. In this study we found that 92% isolates were coagulase positive but the rest of the strains were coagulase-negative, though they were found to be *Staphylococcus aureus* confirmed by PCR analysis using 16S rRNA primers which is specific for this species. This finding is correlated with the findings of Korman [31]. Matthews et al. and Rukumani et al. [32, 33] also found atypical coagulase-negative *Staphylococcus aureus* from food and clinical specimen, respectively. Sanford et al. [34] reported that most clinical strains of *Staphylococcus aureus* associated with pneumonia produced thermostable DNase (88%) and protease (94%). Present study showed that 84% and 81% of the clinical strains produce thermostable DNase and protease, respectively. *Staphylococcus aureus* resistant to methicillin are life threatening bacteria in hospital settings [5]. Studies show that the majority of MRSA strains are associated with hospital-acquired colonization and infections [35]. All *Staphylococcus aureus* strains isolated in this study were multidrug resistant. PCR amplification of *mecA* gene was positive in the 70% of isolates. Khan et al. [36] reported that *mecA* harbouring multidrug resistant

*Staphylococcus aureus* strains were found in hospital personnel in a premier hospital in North India. Prevalence rate of MRSA was 44% in a Tertiary Care Hospital, AIIMS, New Delhi [35]. In the present study we have found that the prevalence rate of MRSA is 70%. This finding is supported by Boucher and Corey [5]. They reported that the frequency of methicillin-resistant *Staphylococcus aureus* (MRSA) infections increases continuously in hospital-associated infection. Increased prevalence of infection due to MRSA led to the use of glycopeptides for therapeutic purpose [10]. We found that 54.3% of the methicillin-resistant *Staphylococcus aureus* isolates were also resistant to vancomycin. Vancomycin resistance was also found from intensive care units of tertiary care hospitals in Hyderabad among MRSA isolates [37]. Yaseen et al. [38] reported high prevalence of VRSA among multidrug-resistance MRSA from Al-Jumhuory Teaching Hospital Patients in Mosul, Iraq, and that is similar to our results. Tiwari and Sen [39] also reported the emergence of vancomycin resistant *Staphylococcus aureus* (VRSA) from the northern part of India. The *nuc* gene is used for identification for *Staphylococcus aureus* strains [21]. Among the 100 clinical samples, those that were identified as *Staphylococcus aureus* 84% were found to be *nuc* positive. Sahebnaasagh et al. [40] found 80.2% isolates to be *nuc* positive in hospitals of Tehran, Iran. In our study the percentage of *hly* gene in *Staphylococcus aureus* isolates was 40. This study can be compared with the study performed by Rusenova et al. [41] who showed that thirty-one MRSA isolates (42.5%) were positive for beta toxin. Our data though could not cover the entire population; however, at least in the premise of this hospital, it can be said that MRSA and VRSA are prevalent in the hospital environment. Hereby, it is suggested that there should be periodic review of hospital-associated infections including antimicrobial sensitivity testing. It would be helpful in making antibiotic policy for infection control and reducing the incidence of multidrug resistant MRSA and VRSA.

## 5. Conclusion

The current study depicts the high level of multidrug resistant *Staphylococcus aureus* infections in Surgical Ward, Orthopedic Ward, and Burn and Wound Section of a hospital environment. The emergence of multidrug resistant forms of pathogenic *Staphylococcus aureus* is a worldwide problem in clinical medicine. The prevalence of MRSA isolates is increasing in hospital settings and these isolates are more resistant to vancomycin than previously isolated MRSA. A rapid, conventional identification method, based on phenotypic and genotypic characters, is suitable in clinical laboratory procedures.

## Competing Interests

The authors declare that they have no competing interests.

## Acknowledgments

The authors are thankful to all the patients for their cooperation in conducting the study. We also thank Dr. T. K. Pathak, Microbiology Laboratory, Midnapore Medical College and Hospital, for providing clinical samples and strains.

## References

- [1] P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Tenover, *Manual of Clinical Microbiology*, American Society for Microbiology, Washington, DC, USA, 8th edition, 2003.
- [2] R. M. Kloos, M. A. Bannister, J. Bannister et al., "Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States," *The Journal of the American Medical Association*, vol. 298, no. 15, pp. 1763–1771, 2007.
- [3] K. Becker, D. Harmsen, A. Mellmann et al., "Development and evaluation of a quality-controlled ribosomal sequence database for 16S ribosomal DNA-based identification of *Staphylococcus* species," *Journal of Clinical Microbiology*, vol. 42, no. 11, pp. 4988–4995, 2004.
- [4] F. R. DeLeo, M. Otto, B. N. Kreiswirth, and H. F. Chambers, "Community-associated methicillin-resistant *Staphylococcus aureus*," *The Lancet*, vol. 375, no. 9725, pp. 1557–1568, 2010.
- [5] H. W. Boucher and G. R. Corey, "Epidemiology of methicillin-resistant *Staphylococcus aureus*," *Clinical Infectious Diseases*, vol. 46, supplement 5, pp. S344–S349, 2008.
- [6] A. Zapun, C. Contreras-Martel, and T. Vernet, "Penicillin-binding proteins and  $\beta$ -lactam resistance," *FEMS Microbiology Reviews*, vol. 32, no. 2, pp. 361–385, 2008.
- [7] M. Matsushashi, M. D. Song, F. Ishino et al., "Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to  $\beta$ -lactam antibiotics in *Staphylococcus aureus*," *Journal of Bacteriology*, vol. 167, no. 3, pp. 975–980, 1986.
- [8] Y. Katayama, T. Ito, and K. Hiramatsu, "A new class of genetic element, staphylococcus cassette chromosome *mec*, encodes methicillin resistance in *Staphylococcus aureus*," *Antimicrobial Agents and Chemotherapy*, vol. 44, no. 6, pp. 1549–1555, 2000.
- [9] T. Ito, Y. Katayama, K. Asada et al., "Structural comparison of three types of staphylococcal cassette chromosome *mec* integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*," *Antimicrobial Agents and Chemotherapy*, vol. 45, no. 5, pp. 1323–1336, 2001.
- [10] K. Rajadurai, K. R. Mani, K. Panneerselvam, M. Mani, M. Bhaskar, and P. Manikandan, "Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus*: a multicentre study," *Indian Journal of Medical Microbiology*, vol. 24, no. 1, pp. 34–38, 2006.
- [11] S. Vidhani, P. L. Mehndiratta, and M. D. Mathur, "Study of methicillin resistant *S. aureus* (MRSA) isolates from high risk patients," *Indian Journal of Medical Microbiology*, vol. 19, no. 2, pp. 13–16, 2001.
- [12] J. S. McDanel, E. N. Perencevich, D. J. Diekema et al., "Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible *Staphylococcus aureus* bloodstream infections among 122 hospitals," *Clinical Infectious Diseases*, vol. 61, no. 3, pp. 361–367, 2015.
- [13] A. Pangercić, S. Bukovski-Simonoski, and B. Barsić, "Lipopeptides and oxazolidinones—novel antibiotics in MRSA infection treatment," *Liječnički Vjesnik*, vol. 132, supplement 1, pp. 11–13, 2010.
- [14] W. B. Chambers and A. U. Pallagrosi, "Gentamicin in the treatment of staphylococcal infections," *Journal of International Medical Research*, vol. 5, no. 6, pp. 442–449, 1977.
- [15] M. Cruciani and D. Bassetti, "The fluoroquinolones as treatment for infections caused by Gram-positive bacteria," *Journal of Antimicrobial Chemotherapy*, vol. 33, no. 3, pp. 403–417, 1994.
- [16] A. Van Belkum and H. Verbrugh, "40 Years of methicillin resistant *Staphylococcus aureus*," *The British Medical Journal*, vol. 323, no. 7314, pp. 644–645, 2001.
- [17] S. Biswas, A. Karmakar, and C. Ghosh, "Multidrug resistant pathogenic *Staphylococcus aureus* in the pimples," *Medical Science*, vol. 16, pp. 41–50, 2015.
- [18] G. A. Lancefield and S. R. Tatum, "*Staphylococcus aureus*," in *Compendium of Methods for the Microbiological Examination of Foods*, C. Vanderzant and D. F. Splittstoesser, Eds., pp. 533–550, American Public Health Association, Washington, DC, USA, 3rd edition, 1992.
- [19] S. R. Mondy and G. A. Bohach, "Use of multiplex PCR to detect classical and newly described pyrogenic toxin genes in *Staphylococcal* isolates," *Journal of Clinical Microbiology*, vol. 37, no. 10, pp. 3411–3414, 1999.
- [20] K. Zhang, J.-A. McClure, S. Elsayed, T. Louie, and J. M. Conly, "Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome *mec* types I to V in methicillin-resistant *Staphylococcus aureus*," *Journal of Clinical Microbiology*, vol. 43, no. 10, pp. 5026–5033, 2005.
- [21] O. G. Brakstad, K. Aasbakk, and J. A. Maeland, "Detection of *Staphylococcus aureus* by polymerase chain reaction amplification of the *nuc* gene," *Journal of Clinical Microbiology*, vol. 30, no. 7, pp. 1654–1660, 1992.
- [22] S. Jarraud, C. Mouton, J. Thioulouse et al., "Relationships between *Staphylococcus aureus* genetic background, virulence factors, *agr* groups (alleles), and human disease," *Infection and Immunity*, vol. 70, no. 2, pp. 631–641, 2002.
- [23] E. B. Blair, J. S. Emerson, and A. H. Tull, "A new medium, salt mannitol plasma agar, for the isolation of *Staphylococcus aureus*," *American Journal of Clinical Pathology*, vol. 47, no. 1, pp. 30–39, 1967.
- [24] G. H. Chapman, "The significance of sodium chloride in studies of staphylococci," *Journal of bacteriology*, vol. 50, pp. 201–203, 1945.

- [25] R. Cruickshank, J. P. Duguid, B. P. Marmion, and R. H. A. Swain, *Medical Microbiology*, vol. II, Churchill Livingstone, Edinburgh, UK, 12th edition, 1975.
- [26] A. Swan, "The use of a bile-aesculin medium and of Maxted's technique of Lancefield grouping in the identification of enterococci (Group D *Streptococci*)," *Journal of Clinical Pathology*, vol. 7, no. 2, pp. 160–163, 1954.
- [27] J. D. Rodgers, J. J. McCullagh, P. T. McNamee, J. A. Smyth, and H. J. Ball, "Comparison of *Staphylococcus aureus* recovered from personnel in a poultry hatchery and in broiler parent farms with those isolated from skeletal disease in broilers," *Veterinary Microbiology*, vol. 69, no. 3, pp. 189–198, 1999.
- [28] A. W. Bauer, W. M. Kirby, J. C. Sherris, and M. Turck, "Antibiotic susceptibility testing by a standardized single disk method," *American Journal of Clinical Pathology*, vol. 45, no. 4, pp. 493–496, 1966.
- [29] CLSI, "Performance standards for antimicrobial susceptibility testing. Twenty-fifth informational supplement," CLSI Document M100-S25, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2015.
- [30] P. Vijayalakshmi, "Incidence of *Staphylococcus aureus* in surgical site infections in a teaching hospital," *International Journal of Current Microbiology and Applied Sciences*, vol. 4, no. 4, pp. 32–34, 2015.
- [31] R. Z. Korman, "Coagulase-negative mutants of *Staphylococcus aureus*: genetic studies," *Journal of Bacteriology*, vol. 86, pp. 363–369, 1963.
- [32] K. R. Matthews, J. Roberson, B. E. Gillespie, D. A. Luther, and S. P. Oliver, "Identification and differentiation of coagulase-negative *Staphylococcus aureus* by polymerase chain reaction," *Journal of Food Protection*, vol. 60, no. 6, pp. 686–688, 1997.
- [33] D. V. Rukumani, D. R. Ardita, E. M. Shankar et al., "Recalcitrant coagulase-negative methicillin-sensitive *Staphylococcus aureus* in an extremely low-birth-weight pre-term infant with thrombocytopaenia," *JMM Case Reports*, 2014.
- [34] B. A. Sanford, V. L. Thomas, M. A. Ramsay, and T. O. Jones, "Characterization of clinical strains of *Staphylococcus aureus* associated with pneumonia," *Journal of Clinical Microbiology*, vol. 24, no. 1, pp. 131–136, 1986.
- [35] A. Tyagi, A. Kapil, and P. Singh, "Incidence of methicillin resistant *Staphylococcus aureus* (MRSA) in pus samples at a Tertiary Care Hospital, AIIMS, New Delhi," *Journal, Indian Academy of Clinical Medicine*, vol. 9, no. 1, pp. 33–35, 2008.
- [36] A. U. Khan, A. Sultan, A. Tyagi et al., "Amplification of *mecA* gene in multi-drug resistant *Staphylococcus aureus* strains from hospital personnel," *Journal of Infection in Developing Countries*, vol. 1, no. 3, pp. 289–295, 2007.
- [37] V. Thati, C. T. Shivannavar, and S. M. Gaddad, "Vancomycin resistance among methicillin resistant *Staphylococcus aureus* isolates from intensive care units of tertiary care hospitals in Hyderabad," *Indian Journal of Medical Research*, vol. 134, no. 11, pp. 704–708, 2011.
- [38] I. H. Yaseen, A. Y. Shareef, and A. S. Daoud, "High prevalence of multidrug-resistance MRSA and VRSA of different infections from Al-Jumhuory teaching hospital patients in Mosul," *Journal of Life Sciences*, vol. 7, no. 12, pp. 1255–1259, 2013.
- [39] H. K. Tiwari and M. R. Sen, "Emergence of vancomycin resistant *Staphylococcus aureus* (VRSA) from a tertiary care hospital from northern part of India," *BMC Infectious Diseases*, vol. 6, article 156, 2006.
- [40] R. Sahebnasagh, H. Saderi, and P. Owlia, "The prevalence of resistance to methicillin in *Staphylococcus aureus* strains isolated from patients by PCR Method for detection of *mecA* and *nuc* genes," *Iranian Journal of Public Health*, vol. 43, no. 1, pp. 84–92, 2014.
- [41] N. Rusenova, W. Gebreyes, M. Koleva et al., "Comparison of three methods for routine detection of *Staphylococcus aureus* isolated from bovine mastitis," *Kafkas Universitesi Veteriner Fakultesi Dergisi*, vol. 19, no. 4, pp. 709–712, 2013.